Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

AKT is frequently deregulated in cancer, making it an attractive anticancer drug target. CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Cancer Ther
Päätekijät: Yap, Timothy A., Walton, Mike I., Hunter, Lisa-Jane K., Valenti, Melanie, de Haven Brandon, Alexis, Eve, Paul D., Ruddle, Ruth, Heaton, Simon P., Henley, Alan, Pickard, Lisa, Vijayaraghavan, Gowri, Caldwell, John J., Thompson, Neil T., Aherne, Wynne, Raynaud, Florence I., Eccles, Suzanne A., Workman, Paul, Collins, Ian, Garrett, Michelle D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944842/
https://ncbi.nlm.nih.gov/pubmed/21191045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0760
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia